G
Gilles Wandeler
Researcher at University of Bern
Publications - 180
Citations - 5530
Gilles Wandeler is an academic researcher from University of Bern. The author has contributed to research in topics: Medicine & Hepatitis B virus. The author has an hindex of 28, co-authored 139 publications receiving 4398 citations. Previous affiliations of Gilles Wandeler include Cheikh Anta Diop University.
Papers
More filters
Journal ArticleDOI
Modelling the impact of different testing strategies for HCV infection in Switzerland.
Maryam Sadeghimehr,Barbara Bertisch,Christian Schaetti,Gilles Wandeler,Jean-Luc Richard,Claude Scheidegger,Olivia Keiser,Janne Estill,Janne Estill +8 more
TL;DR: Only large-scale screening of the general population could substantially accelerate the rate of HCV diagnosis and treatment in Switzerland and other countries with similar epidemics, but this implies screening of a large population with low prevalence, and may trigger considerable numbers of false-positive and borderline test results.
Journal ArticleDOI
Hepatitis delta infection among persons living with HIV in Europe
Charles Béguelin,Andrew Atkinson,Anders Boyd,Karolin Falconer,N. Kirkby,Franziska Suter-Riniker,H. Günthard,J.K. Rockstroh,Amanda Mocroft,Andri Rauch,Lars Peters,Gilles Wandeler +11 more
TL;DR: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe as mentioned in this paper .
Posted ContentDOI
Diagnostic performance of non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa: a Bayesian individual patient data meta-analysis
Asgeir Johannessen,Alexander J. Stockdale,M. Henrion,E. C. Okeke,Moussa Seydi,Gilles Wandeler,Mark W. Sonderup,C Wendy Spearman,Michael J. Vinikoor,Edford Sinkala,Hailemichael Desalegn,Fatou Ba Fall,Nick Riches,Pantong Davwar,Mary Duguru,Tongai Maponga,Jantjie Taljaard,P. Matthews,Madelen Andersson,Roger Sombié,Yusuke Shimakawa,Maud Lemoine +21 more
TL;DR: The World Health Organization (WHO) recommended APRI threshold of 2.0 is too high to diagnose cirrhosis in sub-Saharan Africa and new and optimised rule-in and rule-out thresholds are identified, with direct consequences for treatment guidelines in this setting.
Journal ArticleDOI
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.
Jacobus Herderschee,Tytti Heinonen,Craig Fenwick,Irene T. Schrijver,Khalid Ohmiti,Darius Moradpour,Matthias Cavassini,Giuseppe Pantaleo,Thierry Roger,Thierry Calandra,K. Aebi-Popp,A. Anagnostopoulos,Manuel Battegay,Enos Bernasconi,Jürg Böni,Dominique L Braun,Heiner C. Bucher,A. Calmy,M. Cavassini,Angela Ciuffi,G. Dollenmaier,M Egger,L Elzi,Jan Fehr,Jacques Fellay,Hansjakob Furrer,Christoph A Fux,Günthard Hf,D Haerry,Barbara Hasse,Hans H. Hirsch,Matthias Hoffmann,Irene Hösli,M. Huber,Christian R Kahlert,Laurent Kaiser,Olivia Keiser,Thomas Klimkait,Roger D. Kouyos,Helen Kovari,B Ledergerber,Gladys Martinetti,B Martinez de Tejada,Catia Marzolini,Karin J. Metzner,Nicolas Müller,Dunja Nicca,Paolo Paioni,G. Pantaleo,M. Perreau,Andri Rauch,Christoph Rudin,Alexandra U. Scherrer,Patrick Schmid,Roberto F. Speck,Marcel Stöckle,Philip E. Tarr,A. Trkola,P. Vernazza,Gilles Wandeler,Rainer Weber,Sabine Yerly +61 more
TL;DR: In this article, the authors used mass cytometry to get a broad and in-depth assessment of blood cell populations of patients with chronic hepatitis C virus (HCV) before and after DAA therapy.
Journal ArticleDOI
Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons.
Amanda Mocroft,Jens D Lundgren,Juergen K. Rockstroh,Inka Aho,Gilles Wandeler,Lars N Nielsen,Simon G. Edwards,Jean-Paul Viard,Karine Lacombe,Gerd Fätkenheuer,Giovanni Guaraldi,Montserrat Laguno,Josep M. Llibre,Hila Elinav,Leo Flamholc,Martin Gisinger,Dzmitry Paduta,Irina Khromova,David Jilich,Błażej Rozpłochowski,Cristiana Oprea,Lars Peters,EuroSIDA study +22 more
TL;DR: HCV coinfection and HCV cure were not associated with DM in this large study, and the biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.